Literature DB >> 24722444

Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN.

Edwin K S Wong1, Holly E Anderson1, Andrew P Herbert2, Rachel C Challis1, Paul Brown3, Geisilaine S Reis1, James O Tellez1, Lisa Strain1, Nicholas Fluck3, Ann Humphrey3, Alison Macleod3, Anna Richards4, Daniel Ahlert1, Mauro Santibanez-Koref1, Paul N Barlow2, Kevin J Marchbank5, Claire L Harris6, Timothy H J Goodship1, David Kavanagh7.   

Abstract

Complement C3 activation is a characteristic finding in membranoproliferative GN (MPGN). This activation can be caused by immune complex deposition or an acquired or inherited defect in complement regulation. Deficiency of complement factor H has long been associated with MPGN. More recently, heterozygous genetic variants have been reported in sporadic cases of MPGN, although their functional significance has not been assessed. We describe a family with MPGN and acquired partial lipodystrophy. Although C3 nephritic factor was shown in family members with acquired partial lipodystrophy, it did not segregate with the renal phenotype. Genetic analysis revealed a novel heterozygous mutation in complement factor H (R83S) in addition to known risk polymorphisms carried by individuals with MPGN. Patients with MPGN had normal levels of factor H, and structural analysis of the mutant revealed only subtle alterations. However, functional analysis revealed profoundly reduced C3b binding, cofactor activity, and decay accelerating activity leading to loss of regulation of the alternative pathway. In summary, this family showed a confluence of common and rare functionally significant genetic risk factors causing disease. Data from our analysis of these factors highlight the role of the alternative pathway of complement in MPGN.
Copyright © 2014 by the American Society of Nephrology.

Entities:  

Keywords:  complement; immunology; membranoproliferative GN (MPGN)

Mesh:

Substances:

Year:  2014        PMID: 24722444      PMCID: PMC4214516          DOI: 10.1681/ASN.2013070732

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  38 in total

1.  On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production.

Authors:  R E Spitzer; A E Stitzel; G Tsokos
Journal:  Clin Immunol Immunopathol       Date:  1992-09

2.  Toward a working definition of C3 glomerulopathy by immunofluorescence.

Authors:  Jean Hou; Glen S Markowitz; Andrew S Bomback; Gerald B Appel; Leal C Herlitz; M Barry Stokes; Vivette D D'Agati
Journal:  Kidney Int       Date:  2013-09-25       Impact factor: 10.612

3.  The immunogloblin nature of nephritic factor (NeF).

Authors:  D M Scott; N Amos; J G Sissons; P J Lachmann; D K Peters
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

Review 4.  Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.

Authors:  Sanjeev Sethi; Carla M Nester; Richard J H Smith
Journal:  Kidney Int       Date:  2011-12-07       Impact factor: 10.612

5.  Structural and functional characterization of the product of disease-related factor H gene conversion.

Authors:  Andrew P Herbert; David Kavanagh; Conny Johansson; Hugh P Morgan; Bärbel S Blaum; Jonathan P Hannan; Paul N Barlow; Dušan Uhrín
Journal:  Biochemistry       Date:  2012-02-22       Impact factor: 3.162

6.  Basement membrane-changes in membranoproliferative glomerulonephritis: a light and electron microscopic study.

Authors:  D Anders; W Thoenes
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1975-12-31

7.  Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.

Authors:  Anna Richards; Elizabeth J Kemp; M Kathryn Liszewski; Judith A Goodship; Anne K Lampe; Ronny Decorte; M Hamza Müslümanoğlu; Salih Kavukcu; Guido Filler; Yves Pirson; Leana S Wen; John P Atkinson; Timothy H J Goodship
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

8.  Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.

Authors:  Veronique Frémeaux-Bacchi; Elizabeth C Miller; M Kathryn Liszewski; Lisa Strain; Jacques Blouin; Alison L Brown; Nadeem Moghal; Bernard S Kaplan; Robert A Weiss; Karl Lhotta; Gaurav Kapur; Tej Mattoo; Hubert Nivet; William Wong; Sophie Gie; Bruno Hurault de Ligny; Michel Fischbach; Ritu Gupta; Richard Hauhart; Vincent Meunier; Chantal Loirat; Marie-Agnès Dragon-Durey; Wolf H Fridman; Bert J C Janssen; Timothy H J Goodship; John P Atkinson
Journal:  Blood       Date:  2008-09-16       Impact factor: 22.113

9.  C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.

Authors:  Agustín Tortajada; Hugo Yébenes; Cynthia Abarrategui-Garrido; Jaouad Anter; Jesús M García-Fernández; Rubén Martínez-Barricarte; María Alba-Domínguez; Talat H Malik; Rafael Bedoya; Rocío Cabrera Pérez; Margarita López Trascasa; Matthew C Pickering; Claire L Harris; Pilar Sánchez-Corral; Oscar Llorca; Santiago Rodríguez de Córdoba
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

10.  C3 glomerulopathy: consensus report.

Authors:  Matthew C Pickering; Vivette D D'Agati; Carla M Nester; Richard J Smith; Mark Haas; Gerald B Appel; Charles E Alpers; Ingeborg M Bajema; Camille Bedrosian; Michael Braun; Mittie Doyle; Fadi Fakhouri; Fernando C Fervenza; Agnes B Fogo; Véronique Frémeaux-Bacchi; Daniel P Gale; Elena Goicoechea de Jorge; Gene Griffin; Claire L Harris; V Michael Holers; Sally Johnson; Peter J Lavin; Nicholas Medjeral-Thomas; B Paul Morgan; Cynthia C Nast; Laure-Hélène Noel; D Keith Peters; Santiago Rodríguez de Córdoba; Aude Servais; Sanjeev Sethi; Wen-Chao Song; Paul Tamburini; Joshua M Thurman; Michael Zavros; H Terence Cook
Journal:  Kidney Int       Date:  2013-10-30       Impact factor: 10.612

View more
  23 in total

Review 1.  Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities.

Authors:  Baris Akinci; Rasimcan Meral; Elif Arioglu Oral
Journal:  Curr Diab Rep       Date:  2018-11-08       Impact factor: 4.810

Review 2.  Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

Authors:  An S De Vriese; Sanjeev Sethi; Jens Van Praet; Karl A Nath; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

3.  C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.

Authors:  Edwin K S Wong; Kevin J Marchbank; Hannah Lomax-Browne; Isabel Y Pappworth; Harriet Denton; Katie Cooke; Sophie Ward; Amy-Claire McLoughlin; Grant Richardson; Valerie Wilson; Claire L Harris; B Paul Morgan; Svetlana Hakobyan; Paul McAlinden; Daniel P Gale; Heather Maxwell; Martin Christian; Roger Malcomson; Timothy H J Goodship; Stephen D Marks; Matthew C Pickering; David Kavanagh; H Terence Cook; Sally A Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2021-09-22       Impact factor: 8.237

4.  Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease.

Authors:  Rachel C Challis; Troels Ring; Yaobo Xu; Edwin K S Wong; Oliver Flossmann; Ian S D Roberts; Saeed Ahmed; Michael Wetherall; Giedrius Salkus; Vicky Brocklebank; Julian Fester; Lisa Strain; Valerie Wilson; Katrina M Wood; Kevin J Marchbank; Mauro Santibanez-Koref; Timothy H J Goodship; David Kavanagh
Journal:  J Am Soc Nephrol       Date:  2016-12-14       Impact factor: 10.121

Review 5.  Update on C3 glomerulopathy.

Authors:  Thomas D Barbour; Marieta M Ruseva; Matthew C Pickering
Journal:  Nephrol Dial Transplant       Date:  2014-10-17       Impact factor: 5.992

6.  Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R.

Authors:  Marcell Cserhalmi; Barbara Uzonyi; Nicolas S Merle; Dorottya Csuka; Edgar Meusburger; Karl Lhotta; Zoltán Prohászka; Mihály Józsi
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

7.  A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome.

Authors:  Rachel C Challis; Geisilaine S R Araujo; Edwin K S Wong; Holly E Anderson; Atif Awan; Anthony M Dorman; Mary Waldron; Valerie Wilson; Vicky Brocklebank; Lisa Strain; B Paul Morgan; Claire L Harris; Kevin J Marchbank; Timothy H J Goodship; David Kavanagh
Journal:  J Am Soc Nephrol       Date:  2015-10-21       Impact factor: 10.121

8.  The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.

Authors:  E H Phillips; J P Westwood; V Brocklebank; E K S Wong; J O Tellez; K J Marchbank; S McGuckin; D P Gale; J Connolly; T H J Goodship; D Kavanagh; M A Scully
Journal:  J Thromb Haemost       Date:  2016-01-11       Impact factor: 5.824

9.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08

10.  A haplotype in CFH family genes confers high risk of rare glomerular nephropathies.

Authors:  Yin Ding; Weiwei Zhao; Tao Zhang; Hao Qiang; Jianping Lu; Xin Su; Shuzhen Wen; Feng Xu; Mingchao Zhang; Haitao Zhang; Caihong Zeng; Zhihong Liu; Huimei Chen
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.